The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups

  title={The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups},
  author={Shivakumar Chitturi and Vincent Wai‐Sun Wong and Wah‐Kheong Chan and Grace Lai‐Hung Wong and Simon Kin-hung Wong and Jose D. Sollano and Yen‐Hsuan Ni and Chun-Jen Liu and Yu-Cheng Lin and Laurentius A Lesmana and Seung Up Kim and Etsuko Hashimoto and Masahide Hamaguchi and Khean Lee Goh and Jian-Gao Fan and Ajay Kumar Duseja and Yock Young Dan and Yogesh K. Chawla and Geoffrey C. Farrell and Henry Lik-Yuen Chan},
  journal={Journal of Gastroenterology and Hepatology},
  pages={86 - 98}
Yock Young Dan served as an advisory board member and has received research grants from AbbVie, Bristol-Myers Squibb, and Gilead Sciences. : This project was supported by a grant from the Journal of Gastroenterology and Hepatology Foundation. 

Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations

There are increasing data on the association between non‐alcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVD), and the need for further research is needed to establish a causative mechanism.

Modelling NAFLD disease burden in four Asian regions—2019‐2030

Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) account for an increasing proportion of liver disease in the Asia‐Pacific region. Many areas in the region are

Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review

To conduct a systematic literature review to identify recent epidemiological, biomarker, genetic and clinical evidence that expands our understanding of nonalcoholic fatty liver disease (NAFLD) as a

Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)

Non-alcoholic fatty liver disease (NAFLD) is an acquired metabolic stress-induced liver disease associated closely with genetic susceptibility and insulin resistance (IR), the spectrum of the disease

Non‐alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: A systematic review and meta‐analysis

A systematic literature review and meta‐analysis is performed aiming to investigate the association between NAFLD and PCOS among premenopausal PCOS patients.

Nonalcoholic fatty liver disease burden: Australia, 2019–2030

A Markov model was used to forecast NAFLD burden in Australia through 2030 and showed clear trends in increasing levels of advanced liver disease and primary liver cancer in Australia.

Development and validation of a simple risk model to predict major cancers for patients with nonalcoholic fatty liver disease

To recognize risk factors and build up and validate a simple risk model predicting 8‐year cancer events after nonalcoholic fatty liver disease (NAFLD), a simplerisk model is built up and validated.

Assessment and Management of Non-alcoholic Fatty Liver Disease

  • D. Wai
  • Medicine
    The Singapore Family Physician
  • 2021
Currently the best treatment for NAFLD is weight loss, and the proven method would be dieting with regular exercises, and Vitamin E and pioglitazoles are promising medications for treatingNAFLD, but each has its shortcoming.

A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease

Based on study data utilizing imaging studies and biopsy results, GLP-1 RAs or SGLT2 inhibitors can benefit NAFLD T2DM patients, whereas DPP-4 inhibitor therapy was not effective for patients with HS.

Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis

The current literature in English language is reviewed to identify the most recent scientific guidelines about NAFLD with the aim to find and critically analyse the main differences and these difference have been discussed in the light of the possible evolution of the scenario ofNAFLD in the next years.



Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis

This data suggests that insulin sensitizing agents such as metformin may be beneficial for NASH, which is a form of progressive fatty liver disease that is strongly associated with insulin resistance.

Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non‐alcoholic steatohepatitis

Gut microbiota modifiers may have beneficial effects of non‐alcoholic fatty liver disease (NAFLD) but randomised controlled trials (RCT) are lacking in children.

Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial

This data indicates thatulin sensitizing agents may be useful in treatment of non‐alcoholic fatty liver disease and may also be beneficial in the treatment of other types of liver disease.

An assessment of statin safety by hepatologists.

Meta‐analysis: insulin sensitizers for the treatment of non‐alcoholic steatohepatitis

Aliment Pharmacol Ther 2010; 32: 1211–1221

Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations

Metabolic syndrome is a known risk factor of cirrhosis in chronic hepatitis B (CHB) and may be a cause of disease progression in patients with these conditions.

Clinical and pathological progression of non‐alcoholic steatohepatitis to hepatocellular carcinoma

Examination of the clinical and pathological course of how NASH progresses to hepatocellular carcinoma (HCC) is examined.

Comparative efficacy of anti‐diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis of randomized and non‐randomized studies

This study sought to provide a comprehensive assessment regarding the effects of anti‐diabetic agents on NAFLD in patients with T2DM.

Review article: HCV genotype 3 – the new treatment challenge

Over the past several years, hepatitis C therapy has been pegylated interferon and ribavirin based. Although protease inhibitor‐based therapy has enhanced response rates in genotype 1, the recent